Ajayrajsinh R. Zala
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Ajayrajsinh R. Zala has a total of 13 co-authors. Here are the top co-authors by number of shared publications:
- Premlata Kumari
Department of Chemistry, Sardar Vallabhbhai National Institute of Technology, Surat, India
3 shared publications - Dhanji. P. Rajani
Microcare Laboratory, Surat, India
1 shared publication Gautam P. Savaliya
School of Sciences P P Savani University Surat Gujarat India
1 shared publicationHarun Patel
1 shared publication- Harun Patel
Department of Pharmaceutical Chemistry, R. C. Patel Institute of Pharmaceutical Education and Research, Shirpur, Dhule 425405, Maharashtra, India
1 shared publication - Hem N. Naik
Department of Chemistry, Sardar Vallabhbhai National Institute of Technology, Surat, India
1 shared publication
Latest Publications
- 12 February 2026
- Published by Wiley in ChemistrySelect
- Vol. 11 (6)
Exploring the Antimycobacterial Potential of Purine‐Piperazine Hybrids via in Vitro and in Silico Approaches
Novel purine‐based piperazine analogs were rationally designed and synthesized using fluoro‐substituted benzoyl chloride as a key intermediate. The synthesized compounds were characterized and evaluated for their potential anti‐tubercular activity. In vitro biological screening revealed that compounds S1C , S1D , and S1F exhibited significant antimycobacterial activity, with MIC values ranging from 8.5 to 18.8 µg/mL. To gain molecular insights into their mechanism of action, molecular docking studies were performed against UDP‐N‐acetylenolpyruvoylglucosamine reductase (MurB) from Mycobacterium tuberculosis. The docking results demonstrated favorable binding affinities, characterised by key hydrogen bonding and hydrophobic interactions at the active site. Additionally, 100 ns molecular dynamics simulations were conducted to assess the stability of the protein–ligand complexes. ADME profiles were predicted using the PreADME server, suggesting acceptable pharmacokinetic and pharmacodynamic properties. Overall, the biological evaluation, computational modeling, and favorable ADME profiles indicate that compounds S1C , S1D , and S1F are potential candidates for anti‐tubercular drug development.
- 12 February 2026
- Published by Wiley in ChemistrySelect
- Vol. 11 (6)
Exploring the Antimycobacterial Potential of Purine‐Piperazine Hybrids via in Vitro and in Silico Approaches
Novel purine‐based piperazine analogs were rationally designed and synthesized using fluoro‐substituted benzoyl chloride as a key intermediate. The synthesized compounds were characterized and evaluated for their potential anti‐tubercular activity. In vitro biological screening revealed that compounds S1C , S1D , and S1F exhibited significant antimycobacterial activity, with MIC values ranging from 8.5 to 18.8 µg/mL. To gain molecular insights into their mechanism of action, molecular docking studies were performed against UDP‐N‐acetylenolpyruvoylglucosamine reductase (MurB) from Mycobacterium tuberculosis. The docking results demonstrated favorable binding affinities, characterised by key hydrogen bonding and hydrophobic interactions at the active site. Additionally, 100 ns molecular dynamics simulations were conducted to assess the stability of the protein–ligand complexes. ADME profiles were predicted using the PreADME server, suggesting acceptable pharmacokinetic and pharmacodynamic properties. Overall, the biological evaluation, computational modeling, and favorable ADME profiles indicate that compounds S1C , S1D , and S1F are potential candidates for anti‐tubercular drug development.
- 2 October 2023
- Published by Wiley in ChemistrySelect
- Vol. 8 (37)
Versatile Therapeutic Values of N‐Containing Heterocycles Benzimidazole, Piperazine and Piperidine Hybrids
Nitrogen‐containing benzimidazole, piperazine, and piperidine are significant pharmacophores in medicinal chemistry and drug development. Many medications, lead compounds, and various reagents have these N‐containing scaffolds. This review concentrated on the development of novel therapeutic agents as well as the broad range of pharmacological actions demonstrated by benzimidazole, piperazine, and piperidine hybrids. The review emphasizes these hybrids′ potential, range, and medical significance. The review also discusses the structural criteria for benzimidazole, piperazine, and piperidine hybrids created by diverse chemists to be physiologically effective against a variety of disorders.
- 2 October 2023
- Published by Wiley in ChemistrySelect
- Vol. 8 (37)
Versatile Therapeutic Values of N‐Containing Heterocycles Benzimidazole, Piperazine and Piperidine Hybrids
Nitrogen‐containing benzimidazole, piperazine, and piperidine are significant pharmacophores in medicinal chemistry and drug development. Many medications, lead compounds, and various reagents have these N‐containing scaffolds. This review concentrated on the development of novel therapeutic agents as well as the broad range of pharmacological actions demonstrated by benzimidazole, piperazine, and piperidine hybrids. The review emphasizes these hybrids′ potential, range, and medical significance. The review also discusses the structural criteria for benzimidazole, piperazine, and piperidine hybrids created by diverse chemists to be physiologically effective against a variety of disorders.
- 24 January 2023
- Published by Taylor & Francis in Journal of Biomolecular Structure and Dynamics
- Vol. 41 (21) , 11518-11534
Synthesis, characterization, molecular dynamic simulation, and biological assessment of cinnamates linked to imidazole/benzimidazole as a CYP51 inhibitor
A class of 2-(1H-imidazol-1-yl)-1-phenylethyl cinnamates 6a-6j and 2-(1H-benzo[d]imidazol-1-yl)-1-phenylethyl cinnamates 7a-7j were synthesized, and their synthesis was validated using various spectroscopic techniques like IR, NMR, and Mass spectrometry. In addition, the compounds were assessed for in-vitro antibacterial against gram-positive and gram-negative strains and in-vitro antifungal against six different fungal strains. Compounds 6 g, 7 b, 7f, and 7 g exhibited significant activity against all bacterial strains ranging from MIC = 12.5-50 µg/mL, and compounds 6 g, 7 b, and 7 g exhibited considerable activity against all fungal strains ranging from MFC = 125-200 µg/mL. A molecular docking study indicated that compounds 6 g, 7 b, 7 g, and 7j could be lodged in the active pocket and inhibit C. albicans Sterol 14α-demethylase (CYP51) protein via various interactions, and these studies validate the antifungal results. Different parameters from the 100 ns MD simulation study are investigated to evaluate the dynamic stability of protein-ligand complexes. According to the MD simulation study, the proposed compounds effectively kept their molecular interaction and structural integrity within the C. albicans Sterol 14-demethylase. Compounds 6 g, 7 b, and 7 g are promising lead compounds in searching for novel antifungal drug-like molecules. Furthermore, in silico ADME indicates that these compounds possess drug-like physicochemical properties to be orally bioavailable. Communicated by Ramaswamy H. Sarma
- 24 January 2023
- Published by Taylor & Francis in Journal of Biomolecular Structure and Dynamics
- Vol. 41 (21) , 11518-11534
Synthesis, characterization, molecular dynamic simulation, and biological assessment of cinnamates linked to imidazole/benzimidazole as a CYP51 inhibitor
A class of 2-(1H-imidazol-1-yl)-1-phenylethyl cinnamates 6a-6j and 2-(1H-benzo[d]imidazol-1-yl)-1-phenylethyl cinnamates 7a-7j were synthesized, and their synthesis was validated using various spectroscopic techniques like IR, NMR, and Mass spectrometry. In addition, the compounds were assessed for in-vitro antibacterial against gram-positive and gram-negative strains and in-vitro antifungal against six different fungal strains. Compounds 6 g, 7 b, 7f, and 7 g exhibited significant activity against all bacterial strains ranging from MIC = 12.5-50 µg/mL, and compounds 6 g, 7 b, and 7 g exhibited considerable activity against all fungal strains ranging from MFC = 125-200 µg/mL. A molecular docking study indicated that compounds 6 g, 7 b, 7 g, and 7j could be lodged in the active pocket and inhibit C. albicans Sterol 14α-demethylase (CYP51) protein via various interactions, and these studies validate the antifungal results. Different parameters from the 100 ns MD simulation study are investigated to evaluate the dynamic stability of protein-ligand complexes. According to the MD simulation study, the proposed compounds effectively kept their molecular interaction and structural integrity within the C. albicans Sterol 14-demethylase. Compounds 6 g, 7 b, and 7 g are promising lead compounds in searching for novel antifungal drug-like molecules. Furthermore, in silico ADME indicates that these compounds possess drug-like physicochemical properties to be orally bioavailable. Communicated by Ramaswamy H. Sarma